The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Integrative Clinical Genomics of Advanced Prostate Cancer
Open accessAbstract
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“The consortium utilized two sequencing and analysis centers, one centralized digital pathology review center, and one centralized data visualization portal (Cerami et al., 2012; Gao et al., 2013; Robinson et al., 2011; Thorvaldsdóttir et al., 2013).”
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 3×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationTrapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“…analysis reveals that the majority of affected individuals with metastatic castration-resistant prostate cancer harbor clinically actionable molecular alterations, highlighting the need for genetic counseling to inform precision medicine in affected individuals with advanced prostate cancer.”
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965 · cited 2×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“…on the PI3K pathway, PIK3CB-specific inhibitors may have utility in affected individuals with mutation, amplification, and/or fusion of this gene (Schwartz et al., 2015); multiple affected individuals who achieved durable (>1 year) responses to PIK3CB-specificin inhibition harbored activating…”
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 1×
“Among chimeric fusion transcripts identified, recurrent ETS fusions (Tomlins et al., 2005) were observed in 84 cases (56%), of which the majority were fused to ERG and others to FLI1, ETV4, and ETV5 (Figure 3B).”
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,007
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Khamidullina, A. I., Abramenko, Y. E., Bruter, A. V., & Tatarskiy, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021263 · Cited by 73
“RB1 is frequently mutated in a number of cancers (7% in total, according to TCGA database), including sarcoma, bladder, endometrial, ovarian, breast, prostate and non-small cell lung (NSCLC) cancers, and the Rb protein is inactivated by high CDK4/6 or CDK2 activity [32,56,57].”
BackgroundDong, X., Liao, W., Zhang, L., Tu, X., Hu, J., Chen, T., Dai, X., Xiong, Y., Liang, W., Ding, C., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.024 · Cited by 72
Molecular Biology and Evolution of Cancer: From Discovery to Action
Somarelli, J. A., Gardner, H. L., Cannataro, V. L., Gunady, E. F., Boddy, A. M., Johnson, N., Fisk, J. N., Gaffney, S. G., Chuang, J. H., Li, S., et al. (2019) · Molecular Biology and Evolution · doi:10.1093/molbev/msz242 · Cited by 69
Hwang, J. H., Seo, J.-H., Beshiri, M. L., Wankowicz, S. A. M., Liu, D., Cheung, A. T. M., Li, J., Qiu, X., Hong, A. L., Botta, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.068 · Cited by 68
Self-citationMolecular model for neuroendocrine prostate cancer progression
Chen, R., Dong, X., & Gleave, M. E. (2018) · British Journal of Urology · doi:10.1111/bju.14207 · Cited by 71
The influence of BRCA2 mutation on localized prostate cancer
Taylor, R. A., Fraser, M. E., Rebello, R. J., Boutros, P. C., Murphy, D. G., Bristow, R. G., & Risbridger, G. P. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0164-8 · Cited by 68
The role of the histone H3 variant CENPA in prostate cancer
Saha, A. K., Contreras-Galindo, R., Niknafs, Y. S., Iyer, M. K., Qin, T., Padmanabhan, K., Siddiqui, J., Palande, M., Wang, C., Qian, B., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010080 · Cited by 70
Self-citationBiomarkers for Prostate Cancer: From Diagnosis to Treatment
Chen, J., Wang, P., Liu, M., Lyu, F., Ma, M., Ren, X., & Gao, X. (2023) · Diagnostics · doi:10.3390/diagnostics13213350 · Cited by 75
“Examples include the FOXA1, SPOP, and IDH1 gene mutations, and the NCOA2 gene gain [93,106,107].”
BackgroundRoyo, F., Zúñiga-García, P., Torrano, V., Loizaga‐Iriarte, A., Sánchez‐Mosquera, P., Ugalde‐Olano, A., González, E., Cortázar, A. R., Palomo, L., Fernández‐Ruiz, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6899 · Cited by 71
Sperger, J. M., Strotman, L. N., Welsh, A. W., Casavant, B. P., Chalmers, Z., Horn, S., Héninger, E., Thiede, S. M., Tokar, J. J., Gibbs, B. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1021 · Cited by 69
Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer
Bellazzo, A., Minin, G. D., & Collavin, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.134 · Cited by 74
Etten, J. L. V., Nyquist, M. D., Li, Y., Yang, R., Ho, Y., Johnson, R., Ondigi, O., Voytas, D. F., Henzler, C. M., & Dehm, S. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0320 · Cited by 68
Huang, R., Chen, Z., He, L., He, N., Xi, Z., Li, Z., Deng, Y., & Zeng, X. (2017) · Theranostics · doi:10.7150/thno.20797 · Cited by 69
Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic OpportunitiesPreprint
Zadra, G., & Loda, M. F. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030569 · Cited by 65
Self-citationAberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology
Boussios, S., Rassy, E., Shah, S., Ioannidou, E., Sheriff, M., & Pavlidis, N. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1951226 · Cited by 69
Cellular determinants and microenvironmental regulation of prostate cancer metastasis
Rycaj, K., Li, H., Zhou, J., Chen, X., & Tang, D. G. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.009 · Cited by 69
Seifert, M., Peitzsch, C., Gorodetska, I., Börner, C., Klink, B., & Dubrovska, A. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007460 · Cited by 68
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
Zhou, S., Hawley, J. R., Soares, F., Grillo, G., Teng, M., Tonekaboni, S. A. M., Hua, J. T., Kron, K. J., Mazrooei, P., Ahmed, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14318-9 · Cited by 69
Lotan, T. L., Tomlins, S. A., Bismar, T. A., van der Kwast, T., Grignon, D. J., Egevad, L., Kristiansen, G., Pritchard, C. C., Rubin, M. A., & Bubendorf, L. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001450 · Cited by 67
Self-citationHintz, H. M., Gallant, J. P., Griend, D. J. V., Coleman, I. M., Nelson, P. S., & LeBeau, A. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1358 · Cited by 68
Self-citationSheehan, B., Guo, C. W., Neeb, A., Paschalis, A., Sandhu, S. K., & Bono, J. S. D. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.06.006 · Cited by 67
Experimental in vitro, ex vivo and in vivo models in prostate cancer research
Sailer, V., Amsberg, G. V., Duensing, S. M., Kirfel, J., Lieb, V., Metzger, E., Offermann, A., Pantel, K., Schüle, R., Taubert, H. W., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00677-z · Cited by 74
Kommagani, R., Szwarc, M. M., Vasquez, Y. M., Peavey, M. C., Mazur, E. C., Gibbons, W. E., Lanz, R. B., DeMayo, F. J., & Lydon, J. P. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005937 · Cited by 68
Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines
Seim, I., Jeffery, P. L., Thomas, P. B., Nelson, C. C., & Chopin, L. K. (2017) · G3 Genes Genomes Genetics · doi:10.1534/g3.117.039909 · Cited by 63
Giri, V. N., Obeid, E. I., Gross, L., Bealin, L., Hyatt, C., Hegarty, S., Montgomery, S. V., Forman, A. D., Bingler, R., Kelly, W. K., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00039 · Cited by 73
Blee, A. M., He, Y., Yang, Y., Ye, Z., Yan, Y., Pan, Y., Ma, T., Dugdale, J. A., Kuehn, E., Kohli, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0653 · Cited by 68
Self-citationFerrari, A. C., Alumkal, J. J., Stein, M. N., Taplin, M., Babb, J. S., Barnett, E. S., Gómez-Pinillos, A., Liu, X., Moore, D. F., DiPaola, R. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1589 · Cited by 71
Self-citationMolecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain
Elshan, N. G. R. D., Rettig, M. B., & Jung, M. E. (2018) · Medicinal Research Reviews · doi:10.1002/med.21548 · Cited by 69
WNT and β-Catenin in Cancer: Genes and Therapy
Jackstadt, R., Hodder, M. C., & Sansom, O. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033628 · Cited by 74
Wen, S., Niu, Y., & Huang, H. (2019) · Asian journal of urology · doi:10.1016/j.ajur.2019.11.001 · Cited by 67
Phillips, J. W., Pan, Y., Tsai, B. L., Xie, Z., Demirdjian, L., Xiao, W., Yang, H. T., Zhang, Y., Lin, C. H., Cheng, D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915975117 · Cited by 65
Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer
Kumaraswamy, A., Leng, K. W., Westbrook, T. C., Yates, J. A., Zhao, S. G., Evans, C. P., Feng, F. Y.-C., Morgan, T. M., & Alumkal, J. J. (2021) · European Urology · doi:10.1016/j.eururo.2021.03.005 · Cited by 66
Self-citationAndrogen receptor mutations for precision medicine in prostate cancer
Shiota, M., Akamatsu, S., Tsukahara, S., Nagakawa, S., Matsumoto, T., & Eto, M. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0140 · Cited by 69
Gupta, S. K., Li, J., Kemeny, G., Bitting, R. L., Beaver, J., Somarelli, J. A., Ware, K. E., Gregory, S. G., & Armstrong, A. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1211 · Cited by 69
Rimar, K. J., Tran, P. T., Matulewicz, R. S., Hussain, M., & Meeks, J. J. (2017) · Cancer · doi:10.1002/cncr.30631 · Cited by 66
Self-citationPrognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
Terada, N., Akamatsu, S., Kobayashi, T., Inoue, T., Ogawa, O., & Antonarakis, E. S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017719215 · Cited by 68
Fan, Y., Zhu, X., Xu, Y., Lu, X., Xu, Y., Wang, M., Xu, H., Ding, J., Ye, X., Fang, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1582 · Cited by 66
Maughan, B. L., Guedes, L. B., Boucher, K. M., Rajoria, G., Liu, Z., Klimek, S., Zoino, R., Antonarakis, E. S., & Lotan, T. L. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-017-0027-4 · Cited by 67
Gonthier, K., Poluri, R. T. K., & Audet‐Walsh, É. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.016 · Cited by 68
Cantafio, M. E. G., Grillone, K., Caracciolo, D., Scionti, F., Arbitrio, M., Barbieri, V., Pensabene, L., Guzzi, P. H., & Martino, M. T. D. (2018) · Microarrays · doi:10.3390/ht7040033 · Cited by 66
Circulating tumor cell profiling for precision oncology
Labib, M., & Kelley, S. O. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12901 · Cited by 68
AR Splicing Variants and Resistance to AR Targeting Agents
Kanayama, M., Lu, C., Luo, J., & Antonarakis, E. S. (2021) · Cancers · doi:10.3390/cancers13112563 · Cited by 68
PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications
Choudhury, A. D. (2022) · The Prostate · doi:10.1002/pros.24372 · Cited by 69
Cell types of origin for prostate cancer
Lee, S. H., & Shen, M. M. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.002 · Cited by 73
Wang, L., Wang, J., Xiong, H., Wu, F., Lan, T., Zhang, Y., Guo, X., Wang, H., Saleem, M., Jiang, C., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.022 · Cited by 66
MicroRNA-449a enhances radiosensitivity by downregulation of c-Myc in prostate cancer cells
Mao, A., Zhao, Q., Zhou, X., Sun, C., Si, J., Zhou, R., Gan, L., & Zhang, H. (2016) · Scientific Reports · doi:10.1038/srep27346 · Cited by 66
mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Statz, C. M., Patterson, S. E., & Mockus, S. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0453-6 · Cited by 65
Genetic Testing: What Problem Are We Trying to Solve?
Hughes, K. S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7899 · Cited by 65
Sumanasuriya, S., Seed, G., Parr, H., Christova, R., Pope, L., Bertan, C. M., Bianchini, D., Rescigno, P., Figueiredo, I., GOODALL, J. C., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.05.030 · Cited by 62
Self-citationRuiz de Porras, V., Font, A., & Aytes, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.033 · Cited by 65
Deregulation of SPOP in Cancer
Zhang, H., Jin, X., & Huang, H. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2801 · Cited by 66
Rege, J., Bandulik, S., Nanba, K., Kosmann, C., Blinder, A., Plain, A., Vats, P., Kumar‐Sinha, C., Lerário, A. M., Else, T., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01498-5 · Cited by 78
Self-citationZhan, Y., Zhang, G., Wang, X., Qi, Y., Bai, S., Li, D., Ma, T., Sartor, O. A., Flemington, E. K., Zhang, H., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0236 · Cited by 66
Xie, Q. M., Liu, Y., Cai, T., Horton, C., Stefanson, J., & Wang, Z. A. (2017) · Nature Communications · doi:10.1038/ncomms14284 · Cited by 71
PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
Virtanen, V., Paunu, K., Ahlskog, J. K., Várnai, R., Sipeky, C., & Sundvall, M. (2019) · Genes · doi:10.3390/genes10080565 · Cited by 67
Chaudagar, K. K., Hieromnimon, H. M., Kelley, A., Labadie, B. W., Shafran, J. S., Rameshbabu, S., Drovetsky, C., Bynoe, K. M., Solanki, A., Markiewicz, E. J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1441 · Cited by 70
Self-citationKoo, K. M., Wee, E. J. H., Mainwaring, P. N., Wang, Y., & Trau, M. (2016) · Small · doi:10.1002/smll.201602161 · Cited by 64
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Rodrigues, D. N., Casiraghi, N. A., Romanel, A., Crespo, M., Miranda, S., Rescigno, P., Figueiredo, I., Riisnaes, R., Carreira, S., Sumanasuriya, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2068 · Cited by 64
Self-citationPARP‐1 regulates DNA repair factor availability
Schiewer, M. J., Mandigo, A. C., Gordon, N., Huang, F., Gaur, S., de Leeuw, R., Zhao, S. G., Evans, J. R., Han, S., Parsons, T., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708816 · Cited by 63
Self-citationHu, C., Xia, H., Bai, S., Zhao, J., Edwards, H. J., Li, X., Yang, Y., Lyu, J., Wang, G., Zhan, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15281 · Cited by 60
Stopsack, K. H. (2020) · European Urology · doi:10.1016/j.eururo.2020.09.024 · Cited by 63
Clinical considerations for the management of androgen indifferent prostate cancer
Berchuck, J. E., Viscuse, P. V., Beltran, H., & Aparicio, A. M. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00332-5 · Cited by 63
Self-citationAssociation between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer
Lozano, R., Salles, D. C., Sandhu, S. K., Aragón, I. M., Thorne, H., López‐Campos, F., Rubio‐Briones, J., Gutiérrez-Pecharromán, A., Maldonado, L., Domenico, T. D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.027 · Cited by 65
Self-citationChaves, L. P., Melo, C. M., Saggioro, F. P., dos Reis, R. B., & Squire, J. A. (2021) · Genes · doi:10.3390/genes12121900 · Cited by 66
Liu, K., Zhang, Y., Du, G., Chen, X., Xiao, L., Jiang, L., Jing, N., Xu, P., Zhao, C., Liu, Y., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183544 · Cited by 69
PARP Inhibitors in Prostate Cancer
Geethakumari, P. R., Schiewer, M. J., Knudsen, K. E., & Kelly, W. K. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0480-2 · Cited by 64
Shi, S., Wang, L., Han, D., Wu, J., Jiao, D., Zhang, K.-L., Chen, J., Li, Y., Yang, F., Zhang, J., et al. (2019) · Theranostics · doi:10.7150/thno.29884 · Cited by 63
Linch, M. D., Goh, G., Hiley, C. T., Shanmugabavan, Y., McGranahan, N., Rowan, A., Wong, Y. N. S., King, H., Furness, A. J. S., Freeman, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx355 · Cited by 62
Self-citationEvaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer
Taavitsainen, S., Annala, M., Ledet, E. M., Beja, K., Miller, P. J., Moses, M. W., Nykter, M., Chi, K. N., Sartor, O. A., & Wyatt, A. W. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00014 · Cited by 64
Kim, T. J., & Koo, K. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155484 · Cited by 64
Vélez, M. G., Kosiorek, H., Egan, J. B., McNatty, A. L., Riaz, I. B., Hwang, S. R., Stewart, G. A., Ho, T. H., Moore, C. N., Singh, P. P., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00430-4 · Cited by 62
PSMA Theranostics: Current Landscape and Future Outlook
Zhang, H., Koumna, S., Pouliot, F., Beauregard, J., & Kolinsky, M. P. (2021) · Cancers · doi:10.3390/cancers13164023 · Cited by 66
Raith, F., O’Donovan, D. H., Lemos, C., Politz, O., & Haendler, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032289 · Cited by 64
“Mutations in p110δ are less frequent and mainly found in mCRPC [19,92].”
BackgroundThe Role of WNT Pathway Mutations in Cancer Development and an Overview of Therapeutic Options
Groenewald, W., Lund, A. H., & Gay, D. M. (2023) · Cells · doi:10.3390/cells12070990 · Cited by 63
“RSPO2 fusion mutations have also been reported in both gastric [54] and prostate cancer [55]; however, all four RSPONDIN proteins have been shown to be overexpressed across many other types [56].”
BackgroundOjo, D., Lin, X., Wong, N., Gu, Y. J., & Tang, D. (2015) · Cancers · doi:10.3390/cancers7040890 · Cited by 64
Multiparametric liquid biopsy analysis in metastatic prostate cancer
Hodara, E., Morrison, G. J., Cunha, A. T., Zainfeld, D. E., Xu, T., Xu, Y., Dempsey, P. W., Pagano, P. C., Bischoff, F. Z., Khurana, A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125529 · Cited by 62
Torquato, S., Pallavajjala, A., Goldstein, A., Toro, P. V., Silberstein, J. L., Lee, J., Nakazawa, M., Waters, I. G., Chu, D. T. W., Shinn, D., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00227 · Cited by 60
Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes
Beebe‐Dimmer, J., Kapron, A. L., Fraser, A. M., Smith, K. R., & Cooney, K. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02808 · Cited by 65
Self-citationSena, L. A., Fountain, J., Velho, P. I., Lim, S. J., Wang, H., Nizialek, E. A., Rathi, N., Nussenzveig, R. H., Maughan, B. L., Vélez, M. G., et al. (2020) · The Oncologist · doi:10.1002/onco.13601 · Cited by 63
Self-citationPisano, C., Tucci, M., Stefano, R. F. D., Turco, F., Scagliotti, G. V., Maïo, M. D., & Buttigliero, C. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103185 · Cited by 62
Sperger, J. M., Emamekhoo, H., McKay, R. R., Stahlfeld, C. N., Singh, A., Chen, X. E., Kwak, L., Gilsdorf, C. S., Wolfe, S. K., Wei, X. X., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00169 · Cited by 62
Self-citationSun, R., Yan, B., Li, H., Ding, D., Wang, L., Pang, J., Ye, D., & Huang, H. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0285 · Cited by 65
Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications
Deng, Q., & Tang, D. G. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0217 · Cited by 64
Galeterone for the treatment of advanced prostate cancer: the evidence to date
Antonarakis, E. S., & Bastos, D. A. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s93941 · Cited by 60
Lohiya, V., Aragon‐Ching, J. B., & Sonpavde, G. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34535 · Cited by 60
Faivre, E. J., Wilcox, D. M., Li, X., Hessler, P., Torrent, M., He, W. A., Uziel, T., Albert, D. H., McDaniel, K. F., Kati, W. M., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0221 · Cited by 64
Petrovics, G., Price, D. K., Lou, H., Chen, Y., Garland, L., Bass, S. E., Jones, K. M., Kohaar, I., Ali, A., Ravindranath, L., et al. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0114-1 · Cited by 61
Self-citationKhani, F., Wobker, S. E., Hicks, J. L., Robinson, B. D., Barbieri, C. E., Marzo, A. M. D., Epstein, J. I., Pritchard, C. C., & Lotan, T. L. (2019) · The Journal of Pathology · doi:10.1002/path.5283 · Cited by 61
Self-citationDickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer
Wise, D. R., Schneider, J. A., Armenia, J., Febles, V. A., McLaughlin, B. E., Brennan, R., Thoren, K. L., Abida, W. M., Sfanos, K. S., Marzo, A. M. D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00097 · Cited by 62
Self-citationPatel, S. A., Rodrigues, P., Wesolowski, L., & Vanharanta, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01127-6 · Cited by 57
ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade
Liu, X., Cen, X., Wu, R., Chen, Z., Xie, Y., Wang, F., Shan, B., Zeng, L., Zhou, J., Xie, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39920-5 · Cited by 60
Self-citationZanvit, P., van Dyk, D., Fazenbaker, C., McGlinchey, K., Luo, W., Pezold, J. M., Meekin, J., Chang, C.-Y., Carrasco, R. A., Breen, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci169655 · Cited by 60
Germline genetic variants in men with prostate cancer and one or more additional cancers
Pilie, P. G., Johnson, A., Hanson, K., Dayno, M., Kapron, A. L., Stoffel, E. M., & Cooney, K. A. (2017) · Cancer · doi:10.1002/cncr.30817 · Cited by 59
Self-citationMechanisms of DNA damage repair in adult stem cells and implications for cancer formation
Weeden, C. E., & Asselin-Labat, M.-L. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.015 · Cited by 61
O'Kane, G. M., Connor, A. A., & Gallinger, S. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.007 · Cited by 61
Perera‐Bel, J., Hutter, B., Heining, C., Bleckmann, A., Fröhlich, M., Fröhling, S., Glimm, H., Brors, B., & Beißbarth, T. (2018) · Genome Medicine · doi:10.1186/s13073-018-0529-2 · Cited by 60
Duan, L., Chen, Z., Lu, J. K., Liang, Y., Wang, M., Roggero, C. M., Zhang, Q.-J., Gao, J., Fang, Y., Cao, J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1004 · Cited by 59
Self-citationZhu, Y., Sharp, A., Anderson, C. M., Silberstein, J. L., Taylor, M. N., Lu, C., Zhao, P., Marzo, A. M. D., Antonarakis, E. S., Wang, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.009 · Cited by 59
Self-citationTargeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer
Yamada, Y., Venkadakrishnan, V. B., Mizuno, K., Bakht, M. K., Ku, S., Garcia, M. M., & Beltran, H. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6732 · Cited by 63
Self-citationMolecular landscape of prostate cancer: Implications for current clinical trials
Khemlina, G., Ikeda, S., & Kurzrock, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.07.001 · Cited by 62
Metadata
- Authors
- Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., Beltran, H., Abida, W., Bradley, R. K., Vinson, J., Cao, X., Vats, P., Kunju, L. P., Hussain, M., Feng, F. Y., Tomlins, S. A., Cooney, K. A., Smith, D. C., Brennan, C., Siddiqui, J., Mehra, R., Chen, Y., Rathkopf, D. E., Morris, M. J., Solomon, S. B., Durack, J. C., Reuter, V. E., Gopalan, A., Gao, J., Loda, M., Lis, R. T., Bowden, M., Balk, S. P., Gaviola, G., Sougnez, C., Gupta, M., Yu, E. Y., Mostaghel, E. A., Cheng, H. H., Mulcahy, H., True, L. D., Plymate, S. R., Dvinge, H., Ferraldeschi, R., Flohr, P., Miranda, S., Zafeiriou, Z., Tunariu, N., Mateo, J., Perez-Lopez, R., Demichelis, F., Robinson, B. D., Schiffman, M., Nanus, D. M., Tagawa, S. T., Sigaras, A., Eng, K. W., Elemento, O., Sboner, A., Heath, E. I., Scher, H. I., Pienta, K. J., Kantoff, P., de Bono, J. S., Rubin, M. A., Nelson, P. S., Garraway, L. A., Sawyers, C. L., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Memorial Sloan Kettering Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden NHS Foundation Trust (GB)
- Howard Hughes Medical Institute (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- University of Washington Medical Center (US)
- University of Trento (IT)
- Cornell University (US)
- Wayne State University (US)
- Johns Hopkins University (US)
- Corresponding author
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- ORCID
- Robinson, Dan
- Schultz, Nikolaus
- Mosquera, Juan-Miguel
- Montgomery, Bruce
- Taplin, Mary-Ellen
- Pritchard, Colin C.
- Attard, Gerhardt
- Beltran, Himisha
- Abida, Wassim
- Bradley, Robert K.
- Vinson, Jake
- Cao, Xuhong
- Vats, Pankaj
- Kunju, Lakshmi P.
- Hussain, Maha
- Feng, Felix Y.
- Tomlins, Scott A.
- Cooney, Kathleen A.
- Smith, David C.
- Brennan, Christine
- Siddiqui, Javed
- Mehra, Rohit
- Chen, Yu
- Rathkopf, Dana E.
- Morris, Michael J.
- Solomon, Stephen B.
- Durack, Jeremy C.
- Gopalan, Anuradha
- Gao, Jianjiong
- Loda, Massimo
- Lis, Rosina T.
- Bowden, Michaela
- Gupta, Manaswi
- Yu, Evan Y.
- Mostaghel, Elahe A.
- Cheng, Heather H.
- Mulcahy, Hyojeong
- True, Lawrence D.
- Plymate, Stephen R.
- Dvinge, Heidi
- Flohr, Penny
- Miranda, Susana
- Zafeiriou, Zafeiris
- Tunariu, Nina
- Demichelis, Francesca
- Robinson, Brian D.
- Schiffman, Marc
- Nanus, David M.
- Tagawa, Scott T.
- Sigaras, Alexandros
- Eng, Kenneth W.
- Elemento, Olivier
- Sboner, Andrea
- Heath, Elisabeth I.
- Scher, Howard I.
- Pienta, Kenneth J.
- Kantoff, Philip
- Rubin, Mark A.
- Nelson, Peter S.
- Garraway, Levi A.
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 5
- Pages
- 1215-1228
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4484602
- OpenAlex
- W1578291413
- Cited by
- 3,645
- References
- 64
- Citations by year
- 2026: 178 · 2025: 258 · 2024: 320 · 2023: 363 · 2022: 360 · 2021: 392 · 2020: 378 · 2019: 346 · 2018: 358 · 2017: 355 · 2016: 263 · 2015: 63
- FWCI
- 273.95
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-07-16)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Cancer Research UK (13239)
- National Institute for Health and Care Research (CL-2008-22-001)
- Prostate Cancer UK (CEO13_2-002, PG12-49)
- National Institutes of Health (DP2OD002750)
- Medical Research Council (MR/M003272/1)
- National Human Genome Research Institute (UM1HG006508)
- National Cancer Institute (P50 CA 90381, R01CA136578, L30 CA111031, K08CA188615, R21CA128352, U01CA111275, P50CA090381, R01CA131945, UO1CA111275, L30 CA103810, R01CA116337, R01CA129435, P50CA069568, K08CA115927, R01CA092629, R01CA155169, R01CA193910, R01CA085912, P30CA008748, P01CA163227, P50CA097186, P50CA186786, P50CA092629, P30CA006516, R01CA193837)
- National Institute of General Medical Sciences (T32GM007266, R01GM107427)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- metastatic castration-resistant prostate cancer, exome sequencing, transcriptome sequencing, actionable genomic alterations, androgen receptor alterations, ETS gene fusions, TP53, PTEN, R-spondin, APC, β-catenin, BRCA2, BRCA1, ATM, germline pathogenic variants, precision medicine
- MeSH terms
- Humans, Male, Mutation, Neoplasm Metastasis, Cohort Studies, Gene Expression Profiling, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
